Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased ...

Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

The regulator conducted a postmarketing trial which suggested increased risk of Guillain-Barré syndrome (GBS) 42 days ...

The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...